The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer-Reference-Cited by-同舟云学术

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Published:2008-08-29 Issue:18 Volume:51 Page:5522-5532
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Folkes Adrian J.¹,Ahmadi Khatereh¹,Alderton Wendy K.¹,Alix Sonia¹,Baker Stewart J.¹,Box Gary¹,Chuckowree Irina S.¹,Clarke Paul A.¹,Depledge Paul¹,Eccles Suzanne A.¹,Friedman Lori S.¹,Hayes Angela¹,Hancox Timothy C.¹,Kugendradas Arumugam¹,Lensun Letitia¹,Moore Pauline¹,Olivero Alan G.¹,Pang Jodie¹,Patel Sonal¹,Pergl-Wilson Giles H.¹,Raynaud Florence I.¹,Robson Anthony¹,Saghir Nahid¹,Salphati Laurent¹,Sohal Sukhjit¹,Ultsch Mark H.¹,Valenti Melanie¹,Wallweber Heidi J.A.¹,Wan Nan Chi¹,Wiesmann Christian¹,Workman Paul¹,Zhyvoloup Alexander¹,Zvelebil Marketa J.¹,Shuttleworth Stephen J.¹

Affiliation:

1. Piramed Pharma, 957 Buckingham Avenue, Slough, Berks SL1 4NL, United Kingdom, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddon Laboratories, Sutton, Surrey, SN2 5NG, United Kingdom and Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, SW3 6JB, United Kingdom

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm800295d

Reference37 articles.

1. Synthesis and Function of 3-Phosphorylated Inositol Lipids

2. The Phosphoinositide 3-Kinase Pathway

3. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

4. PIK3CA is implicated as an oncogene in ovarian cancer

5. High Frequency of Mutations of the PIK3CA Gene in Human Cancers

Cited by 704 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From lab to clinic: The discovery and optimization journey of PI3K inhibitors;European Journal of Medicinal Chemistry;2024-11

2. Autophagy modulation in cancer therapy: Challenges coexist with opportunities;European Journal of Medicinal Chemistry;2024-10

3. 1,3,5-Triazine as a promising scaffold in the development of therapeutic agents against breast cancer;European Journal of Medicinal Chemistry;2024-10

4. Sphingosine-1 phosphate receptor 1 (S1PR1) expression maintains stemness of acute myeloid leukemia stem cells;Cancer Letters;2024-09

5. Targeting the RAS upstream and downstream signaling pathway for cancer treatment;European Journal of Pharmacology;2024-09